



HAVN LIFE

The Future of Psychedelic Therapy

INVESTMENT HIGHLIGHTS

HAVN Life is focused on the rapidly growing field of psychedelic medicine. We have the opportunity to lead the standardization of psychedelic supply to shift human performance and mental health paradigms .

- ✓ **DEFINED ROUTE TO NATURAL HEALTH PRODUCTS MARKET.**
- ✓ **PRODUCT FORMULATION OF EFFECTIVE MICRODOSING OF NOVEL PSYCHOACTIVE COMPOUNDS.**
- ✓ **MANAGEMENT TEAM WITH EXTENSIVE CLINICAL & NHP PRODUCT DEVELOPMENT EXPERIENCE.**
- ✓ **DEVELOPING STATE-OF-THE-ART MYCOLOGY LAB FOR PSYCHEDELIC EXTRACTION.**
- ✓ **PARTNERSHIP WITH CANADIAN VETERANS FOR PHASE 1 PRE-CLINICAL RESEARCH.**
- ✓ **RECEIVE FIRST HEALTH CANADA LICENSE IN 2020.**

DIVERSE MANAGEMENT TEAM



MISSION

Our mission is to unlock human performance using evidence-informed research. We are focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds.



CORE PILLARS

HAVN Labs

- ✓ A GMP laboratory that will be dedicated to growing and developing extraction methodology of psychoactive and psychedelic compound.
- ✓ Standardized supply of psychedelic to support innovative therapies.
- ✓ Health Canada License received.
- ✓ Development of formulations that allow veterans and frontline workers to optimize their mental health.

HAVN Retail

- ✓ HAVN Life will be developing custom formulations that will deliver natural health products with increased bioavailability to support better quality outcomes.
- ✓ In-house product formulation. Through brand acquisition, HAVN Life will also have a defined route to market.
- ✓ Leveraging a highly experienced and proven management team with a track record of building NHP brands.

OUR STORY

HAVN Life is a part of a global community taking an active part in supporting research for microdosing therapies in treating mental health disorders utilizing psychedelics. Working with Veterans and thought leaders in the military, **HAVN** Life is developing innovative clinical trial formulations to aid in the recovery of PTSD and other trauma related disorders.

Through end to end research, extraction, formulation and delivery, we aspire to define and standardize the future of modern medicine. With an extensive team of industry leaders with 20+ years of experience in this space, **HAVN** Life is formulating the next generation of medicine using psychoactive compounds.

COLLABORATION ACROSS DISCIPLINES

Creating positive patient experience and mental health outcomes



Tim Moore

Co-Chief Executive Officer

- Former CEO of Green Growth Brands, from IPO through to Jan 2019, coming off of the CEO role leading the Company to ~\$1 Billion market cap.
- Former President of Clorox Canada and former COO of Synnex Canada.
- Managing Director at Brita North America group, responsible for building a new business organization across B2B and B2C divisions with both branded and private label portfolio.



Susan Chapelle

Co-Chief Executive Officer

- Recognized thought leader in the Canadian Cannabis space.
- Former two term elected politician whom was fundamental in economic development, data driven healthcare changes and infrastructure planning to help alleviate capacity issues.
- 25 years of leadership experience in health, non-profit, and private sectors in Canada.
- Former Director of Government Relations & Affairs at Pasha Brands.
- Former, Associate Researcher at the University of New England.



Gary Leong

Chief Scientific Officer

- Gary was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019. At Aphria, Gary established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions.
- Gary served as the Chief Scientific Officer Jamieson Laboratories in Windsor, ON for fourteen (14) years.



Dr. Ivan Casselman

Chief Psychedelic Officer

- Extensive nutraceutical formulation experience, with several products available in legal cannabis markets in North America.
- Research spanning human use of psychedelics (ethnobotany and ethnopharmacy) to the study of plant science (genetics and analytical chemistry).
- Previous work includes executive level cannabis advisory.
- Formerly on the management team of NextLeaf during IPO Process.

COLLABORATION ACROSS DISCIPLINES



Alexzander Samuelsson

Chief Research Officer

- Lead chemist of a publicly traded extraction company, Alexzander developed intellectual property and patented methods in the extraction of cannabis oils.
- Holds a Bachelor of Science majoring in chemistry at Ryerson University.
- Supported start-ups in their strategy and implementation of capital projects in Canada, Europe, Central and South Asia through his consulting company Development Catalyst.



Eli Dusenbury

Chief Financial Officer

- Mr. Dusenbury has served as consultant for audit and public practice firms in both Canada and the US and has held CFO positions for the following publicly traded companies: Integral Technologies, Inc. (resigned June 2018), YDX Innovation Corp. (resigned May 2019), Isodiol International Inc. (since August 2018) and Chemesis (since September 2018).
- Obtained his Chartered Professional Accountant designation in 2011 and holds a BBA in business and accounting from Capilano University.



Juliana Mollica

Director of Innovation and Quality Assurance

- Led projects as the quality assurance and compliance manager for cannabis and pharmaceutical companies to ensure maintenance of GMP requirements, developing QMS for multi-site projects, compliance training programs, and increasing compliance and quality rates.
- Expertise in applications for Drug Establishment Licence and Site Licenses.
- Successfully obtained more than 100 NPN product licences in a year.

COLLABORATION ACROSS DISCIPLINES



Vic Neufeld
Director

- CEO of Aphria for 5 years during large scale build up to one of the leading cannabis producers in the world.
- CEO of Jamieson Laboratories for 21 years, Canada's largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements where he increased its market share from 7% to 27%.
- 15 years' experience as a CPA and Partner with Ernst & Young.



Rick Brar
Director

- Mr.Brar is the CEO & Chairman of Brains Biocetual Corp. A global manufacturer and distributor of Cannabinoid API.
- Co-Founder and Former CEO of Zenabis Global Inc. one of the leading Canadian LPs with operations in both medical and recreation cannabis.



Tim Laidler
Director

- Tim completed a Master of Counselling at UBC, during which time he spent thousands of volunteer hours helping create the Veterans Transition Network, a non-profit organization helping Canadian Veterans nationwide.
- Tim is the Executive Director of the Institute for Veterans Education and Transition at UBC. The institute focuses on supporting the needs of veterans in the community as well as supporting cutting edge research with Veterans.



Robert Nygren
Executive Co-Chair

- Co-founded ETC3 - Emerging Technology Centre, which provides facilities, funding and advisory services for life science, agritech, cleantech and fintech companies.
- Former CEO of Epic Data, publicly traded software company..
- Former CEO of Fincentric, from inception to \$35m exit.
- A strong background in complex businesses having practiced Corporate Law in Ontario, B.C. and California.



Barinder Rasode
Executive Co-Chair

- Served two terms as elected Councilor for the City of Surrey.
- Served on the Board of BC's largest health authority, Fraser Health, where she was responsible for a budget over \$3 Billion.
- Co-found ed Grow Tech Labs, providing cannabis regulatory expertise with a focus on post-regulated space.
- Founded The National Institute of Cannabis Health and Education (NICHE).

COLLABORATION ACROSS DISCIPLINES



Sheila Copps

Advisor

- The Honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for ten years in the federal cabinet.
- Her work on diversity and inclusion, the environment and young people has left an indelible mark on Canadian public policy. She is the author of two books Nobody's Baby and Worth Fighting For.



Allen Oberman

Advisor

- Mr. Oberman served as CEO for Concordia International, a international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.
- Previously served as the CEO of Sagent Pharmaceuticals Inc., as well as various leadership positions over 14 years including CEO with Teva Pharmaceuticals, Canadas second largest generic pharmaceutical company.
- Currently, Mr. Oberman is on the Board of Directors of Dr. Reddy's Laboratories, one of Indias Largest global pharmaceutical enterprises.




David Mokler

Advisor

- Dr. David Mokler neuropharmacology, psychopharmacology, substance abuse, drug abuse, brain development, dopamine and serotonin including work relevant to the 5HT2a receptors in psychedelics.
- Published on the serotonergic system in the brain, including papers on LSD, MDMA and psychedelics dating back to 1970. He has published in the areas of; Dr. Mokler is interested in discovering novel compounds.

PATH TO MARKET





A lab devoted to the advancement and formulation of regulated and novel psychoactive compounds.

State-of-the-art Facility

Mycology Laboratory

Formulation Capabilities



STATE-OF-THE-ART FACILITY

HAVN Labs operates from a state-of-the-art research facility located in the South Campus at The University of British Columbia.

MYCOLOGY LABORATORY

With the ability to expand into a pilot plant in the same facility.

Able to formulate and manufacture in one location.

FORMULATION CAPABILITIES

HAVN Life has applied for a Health Canada research license which we have secured for 2020. This will allow for the research and development of psychedelic compound formulations to begin prior to securing Licensed Dealer status.

The licensed dealer status will be secured by 2021 and will permit the supply and sale of regulated compounds.



HAVN Labs will work with veterans and PTSD groups across North America to develop strategic evidence based treatment protocols and optimize formulations to study mental well being.

Currently global access to research informed formulations is limited. Those who are studying psychedelics in research studies and academia rely on products that are developed ad hoc for each project.

HAVN Labs will provide the standardized psychedelic compound formulations for academic institutions with isolates and extractions from our facility that will be utilized for clinical trials and as APIs for product.



At **HAVN** Life, we believe that microdosing has the potential to disrupt the nutraceutical industry. We are the only compound formulation company to utilize its expertise across both biopharma and wellness formulations to build evidence-informed human health and wellness. Our standardized, quality-controlled microdosing formulations are based on extensive natural products research and formulating experience.

*“The global market for nutraceuticals will grow at **7.5% CAGR**, according to a new study by PMMI Business Intelligence, from a **\$241 billion market** in 2019 to **\$373 billion** in 2025. In the U.S., the market this year is expected to hit **\$79 billion** in sales.”*

Source: 2019 Nutraceuticals
Market Assessment

WHAT IS MICRODOSING?

Microdosing is a process whereby small doses of a psychoactive compound, typically psychedelics are used. Each dose has the benefits of the psychoactive compound without affecting your day to day functioning which means you are able to work, exercise, socialize, etc, without any of the extrasensory effects that would typically come from taking a psychedelic.



The logo for HAVN RETAIL features a stylized circular icon on the left, composed of two overlapping rings in teal and orange. To the right of the icon, the words "HAVN RETAIL" are written in a clean, sans-serif font. "HAVN" is in teal and "RETAIL" is in orange.

HAVN RETAIL

Through our unique IP and custom formulations **HAVN Life** will enter the natural health food & nutraceutical industry. This will provide robust revenues and consistent growth as industry regulations continue to evolve.

With increasing demand for better quality ingredients, **HAVN** Life will be developing novel IP that will deliver increased bioavailability through emulsion techniques and blends of natural products that work synergistically to produce better quality outcomes.

Our initial psychoactive microdosing products will be derived from novel psychoactive compounds. This does not require Health Canada Licensed Dealer status.

During Phase 1, **HAVN** Retail will formulate and sell products through online retailers and **HAVN** Life's website.

HAVN Life will secure NHP licences as formulations for retail product lines grow.



**FORMULATIONS
WILL PROVIDE:**


Increased
mindfulness



Decreased
Stress & Anxiety




Uplifted Mood
& Creativity



HAVN Life is in the final stages of product development and aims to have products available to nutraceutical retailers by Q1 2021.

As the industry develops advancements in processes and policy, **HAVN** Life is focused on building and maintaining a consistent and high-quality supply chain through in-house development and external partnerships.

ROADMAP



COMPARABLES

Attractive Valuation Relative to Peer Group


	 HAVNLIFE	 champignon <small>B R A N D S</small>	 field trip	 Numinus	 mindmed
Operational Focus	Microdosing/Consumer Brand & Clinical Research	Branded Products	Drug Development & Wellness Clinics	Research & Clinics	Clinical Trials
Market Segment	Health & Wellness	Health & Wellness	Health & Wellness	Medicinal	Medicinal
Public or Private	Q3 IPO	Public	Private	Public	Public
Market Capitalization	C\$13.25M*	C\$75M	C\$65M	C\$25M	C\$154M

Source: Company Filings

*Anticipated pro forma market capitalization post-listing and assuming completion of the various financings referenced on the following page.

GROWING MUSHROOM MARKET

Global Revenue in 2016 - 2024



The global functional food market is expected to reach **\$34.3 Billion USD** by 2024, registering a **CAGR of 8.04%** during the forecast period (2019-2024).

The market studied is expected to experience huge demand for Reishi and Cordyceps and this is why **HAVN** Life has decided to pursue formulations with these mushrooms.

DISCLAIMER

This presentation is confidential and is being issued by HAVN Life (the “Company”) for informational purposes only. Reliance on this presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This presentation may not be copied, reproduced, distributed, discussed or used without the express written consent of the Company or its advisors on its behalf, or for any other purpose than the evaluation by the recipient of a possible investment in the Company.

The Company does not make any representation or warranty as to the accuracy or completeness of the information in this presentation, and the information herein may not be relied upon by you in evaluating the merits of investing in any securities referred to herein. This presentation does not contain, nor does it purport to contain, a summary of all of the material information concerning the Company or the terms and conditions of any potential investment in the Company. If and when you determine to proceed with discussions and investigations regarding a possible investment in the Company, prospective investors are urged to carry out independent investigations in order to determine their interest in investing in the Company.

In furnishing this presentation to the recipient, the Company and its advisors reserve the right to provide the same or similar information to other persons and to enter into agreements with other parties regarding the opportunity described in this presentation and to cease to provide the recipient with information on the opportunity, all without notice to the recipient.

This presentation is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of securities in the United States, Canada or any other jurisdiction. No securities commission or similar authority of the United States, Canada, or any other jurisdiction has reviewed or in any way passed upon this document or the merits of the securities described herein, and any representation to the contrary is an offence.

This presentation does not contain all of the information that would normally appear in a prospectus under applicable Canadian or United States securities laws. Neither the delivery of this presentation, at any time, nor any sale made pursuant hereto, will imply that the information contained herein is correct as of any time subsequent to the date set forth on the cover page hereof or the date at which such information is expressed to be stated, as applicable, and, except as may be required by applicable law, the Company is under no obligation to update any of the information contained herein (including forward looking statements and forward looking information) or to inform the recipient of any matters of which it becomes aware that may affect any matter referred to in this presentation (including, but not limited to, any error or omission which may become apparent after this presentation has been prepared).

This presentation is not intended as an offer or solicitation with respect to the purchase or sale of any financial instrument. If a private placement of the equity securities of the Company occurs, such transaction may not be registered under the Securities Act of 1933, as amended (the “Act”), or the securities laws of any other jurisdiction, and would be conducted in reliance on exemptions from the registration requirements of the Act and other applicable laws and subject to selling and transfer restrictions.

Investing in the Company involves significant risks given the early stage nature of the Company’s business. Prior to investing in the Company, prospective investors are urged to consult with their legal, investment, accounting, tax and other advisors to determine the risks and consequences of an investment in the Company. Prospective investors should not construe the contents of this presentation as investment or legal advice.

This presentation contains certain forward-looking statements and forward-looking information. Forward-looking statements are

frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” “possible,” “projects,” “plans,” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” or “should” occur or be achieved or their negatives or other comparable words. Any forward-looking statements made herein or made elsewhere by the Company are made solely based on information available to the Company as of the date hereof and based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, anticipated events and trends, the economy and other future conditions. As such, they are subject to inherent uncertainties, risks, assumptions and changes in circumstances that are difficult to predict (including but not limited to risks applicable to early stage ventures and cannabis organizations), and in many cases outside of the Company’s control, and you should not rely on such forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any statements about historical results that suggest trends for the Company’s business, any statements of plans, strategies and objectives of management and any statements of expectation or belief regarding future events. “Future-oriented financial information” is forward-looking information about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, and presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Similarly, a “financial outlook” is forward-looking information about prospective financial performance, financial position or cash flows that is based on assumptions about future economic conditions and courses of action that is not presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Future-oriented financial information and financial outlook made herein or made elsewhere by the Company are made solely based on the information available to the Company as of the date hereof and are subject to the same assumptions, risk factors and other qualifications as all other forward-looking information, and presented solely for the purpose of conveying the current anticipated expectations of the Company and may not be appropriate for any other purposes.

Forward-looking statements and forward-looking information address future events and conditions and therefore involve inherent known and unknown risks and uncertainties. Actual results may differ materially from those in the forward looking statements and forward-looking information due to risks facing the Company or due to actual facts differing from the assumptions underlying its predictions.

Certain of the information contained in this presentation concerning the industry and its trends and performance is based upon or derived from information provided by third-party consultants, other industry sources and our research. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of such information and has not independently verified the assumptions upon which any projections are based.

In the event this presentation is considered to be an offering memorandum, a summary of a purchaser’s rights of action and rescission are included in the Appendix hereto.



HAVNLIFE

THANK YOU

IR@HAVNLIFE.COM